{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:11:52Z","timestamp":1790741512422,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015199","name":"Halozyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019608","name":"Lilly Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019393","name":"Relay Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016859","name":"Mersana Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017468","name":"Aptose Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019110","name":"Tessa Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016765","name":"Jounce Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.esmoop.2022.100530","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T11:26:04Z","timestamp":1659266764000},"page":"100530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors"],"prefix":"10.1016","volume":"7","author":[{"given":"E.","family":"Borazanci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Schram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Brana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vieito Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Hallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Maetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Anido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Seoane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100530_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/359076a0","article-title":"Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor","volume":"359","author":"Stewart","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100530_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/336684a0","article-title":"Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells","volume":"336","author":"Williams","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100530_bib3","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1073\/pnas.86.15.5948","article-title":"Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor","volume":"86","author":"Metcalf","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2022.100530_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1210\/endo.139.5.6016","article-title":"Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response","volume":"139","author":"Chesnokova","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.esmoop.2022.100530_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0896-6273(93)90229-K","article-title":"Leukemia inhibitory factor mediates an injury response but not a target-directed developmental transmitter switch in sympathetic neurons","volume":"11","author":"Rao","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.esmoop.2022.100530_bib6","doi-asserted-by":"crossref","first-page":"8680","DOI":"10.1073\/pnas.151180898","article-title":"Dual control of LIF expression and LIF receptor function regulate Stat3 activation at the onset of uterine receptivity and embryo implantation","volume":"98","author":"Cheng","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2022.100530_bib7","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1210\/endo.141.12.7855","article-title":"Leukemia inhibitory factor can substitute for nidatory estrogen and is essential to inducing a receptive uterus for implantation but is not essential for subsequent embryogenesis","volume":"141","author":"Chen","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.esmoop.2022.100530_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1095\/biolreprod.114.118513","article-title":"The LIF-mediated molecular signature regulating murine embryo implantation","volume":"91","author":"Rosario","year":"2014","journal-title":"Bio Reprod"},{"key":"10.1016\/j.esmoop.2022.100530_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1095\/biolreprod.104.034876","article-title":"Leukocyte subpopulations in the uteri of leukemia inhibitory factor knockout mice during early pregnancy","volume":"72","author":"Schofield","year":"2005","journal-title":"Biol Reprod"},{"key":"10.1016\/j.esmoop.2022.100530_bib10","first-page":"977","article-title":"Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression","volume":"30","author":"Kamahora","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.esmoop.2022.100530_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","article-title":"Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring","volume":"569","author":"Shi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100530_bib12","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/s41467-019-11044-9","article-title":"Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100530_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccr.2009.02.011","article-title":"TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma","volume":"15","author":"Pe\u00f1uelas","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100530_bib14","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","article-title":"LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy","volume":"10","author":"Pascual-Garcia","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100530_bib15","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/ncomms6218","article-title":"LIF negatively regulates tumour-suppressor p53 through Stat3\/ID1\/MDM2 in colorectal cancers","volume":"5","author":"Yu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100530_bib16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.18632\/oncotarget.1772","article-title":"LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100530_bib17","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.celrep.2014.04.036","article-title":"LIF mediates proinvasive activation of stromal fibroblasts in cancer","volume":"7","author":"Albrengues","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.esmoop.2022.100530_bib18","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1172\/JCI63428","article-title":"Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance","volume":"123","author":"Liu","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.esmoop.2022.100530_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cytogfr.2015.07.001","article-title":"Leukemia inhibitory factor (LIF)","volume":"26","author":"Nicola","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.esmoop.2022.100530_bib20","first-page":"e877","article-title":"The regulation of leukemia inhibitor factor","volume":"2","author":"Yue","year":"2015","journal-title":"Cancer Cell Microenviron"},{"key":"10.1016\/j.esmoop.2022.100530_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/08830189809043003","article-title":"Leukemia inhibitory factor; part of a large ingathering family","volume":"16","author":"Taupin","year":"1998","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.esmoop.2022.100530_bib22","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1242\/dev.117598","article-title":"LIF signaling in stem cells and development","volume":"142","author":"Onishi","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.esmoop.2022.100530_bib23","article-title":"Relevance of immune infiltration and clinical outcomes in pancreatic ductal adenocarcinoma subtypes","volume":"10","author":"Liu","year":"2021","journal-title":"Frontiers Oncol"},{"key":"10.1016\/j.esmoop.2022.100530_bib24","unstructured":"Borazanci E, Schram A, Bra\u00f1a I, et al. Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated Results. In: Abstract Book of the 44th ESMO Congress (ESMO 2019); 2019 September 27 \u2013 October 1; Barcelona Spain. Ann Oncol 2019;30(5 Suppl):Abstract nr 1196P."},{"key":"10.1016\/j.esmoop.2022.100530_bib25","doi-asserted-by":"crossref","unstructured":"Sinclair A, Hallett R, Giblin P, et al. MSC-1 is a first-in-class humanized monoclonal antibody that modulates the tumor microenvironment by inhibiting a novel cancer immunotherapy target, LIF. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 April 14\u201318; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1751.","DOI":"10.1158\/1538-7445.AM2018-1751"},{"key":"10.1016\/j.esmoop.2022.100530_bib26","doi-asserted-by":"crossref","unstructured":"Candido J, Kar G, Zhang B, et al. AZD0171 (anti-LIF) combines productively with chemotherapy and anti-PD-L1 in mouse models of cancer. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 April 8\u201313. Philadelphia (PA): AACR; Cancer Res 2022;82(12 Suppl):Abstract nr 1293.","DOI":"10.1158\/1538-7445.AM2022-1293"},{"key":"10.1016\/j.esmoop.2022.100530_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4155\/bio.11.28","article-title":"PK-PD modeling of protein drugs: implications in assay development","volume":"3","author":"Roskos","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.esmoop.2022.100530_bib28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.annonc.2021.08.1748","article-title":"Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance","volume":"32","author":"Loriot","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100530_bib29","doi-asserted-by":"crossref","unstructured":"O\u2019Kane P, Macarulla T, Balogun F, et al. A phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma and CD8+ T cell infiltration. In: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research; 2021 April 8-13; New Orleans, LA. Philadelphia, PA: AACR; 2022. Abstract nr CT126.","DOI":"10.1158\/1538-7445.AM2022-CT126"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:59Z","timestamp":1761856139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292200151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S205970292200151X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100530","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100530"}}